

CLEO Delivers Commercial Development Milestone

Highlights

- **CLEO has commenced technology transfer marking the completion of a critical milestone towards the commercial production of its first Ovarian Cancer diagnostic tests**
- **Development will be carried out by global leader in immunoassay technology, R&D Systems, Inc. a subsidiary of Bio-Techne Corporation based in Minneapolis, USA**
- **Final negotiations are underway with selected FDA-registered CMO's ahead of transition to large-scale manufacturing**
- **Milestone achievement represents significant progression along CLEO's strategic pathway towards FDA submission.**

MELBOURNE, AUSTRALIA, 18 March 2025: Ovarian Cancer diagnostics company, **Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company)** is pleased to announce the commencement of technology transfer activities supporting the development of its simple blood test for the early and accurate detection of Ovarian Cancer. This marks the completion of a critical milestone in the manufacturing pathway for CLEO to deliver its commercially available, FDA-compliant diagnostic test kit.

TECHNOLOGY TRANSFER

After successfully completing design transfer, CLEO has commenced the next phase of its strategic development with the commencement of technology transfer. This process involves the transfer of its in-house development activities, including hybridoma cell line development, antibody production and testing, and selection and finalisation of reagents, to a manufacturer to facilitate commercial production.

To assist with this, CLEO has engaged U.S.-based R&D Systems, Inc., a global leader in immunoassay technology and a subsidiary of the Bio-Techne Group, to scale-up and assemble CLEO's proprietary antibodies for use in CLEO's initial Ovarian Cancer test targeted at the surgical triage market. With state-of-the-art production facilities and globally recognised expertise, the partnership with R&D Systems, Inc. ensures the successful progression of commercial prototype development and supports CLEO's transition to large-scale manufacturing. R&D Systems, Inc. will undertake the remaining steps towards pre-production kit assembly and testing.

Following successful testing, CLEO's selected CMO will assist in scaling production capability, in addition to verification and validation activities, ensuring the production of GMP and ISO13485 compliant in-vitro diagnostic (**IVD**) kits for clinical deployment. These test kits will support the

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors

Chair and Non-Executive Director **Adrien Wing**
Chief Executive Officer and Executive Director **Dr Richard Allman**
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**
Non-Executive Director **Lucinda Nolan**

cleodx.com

completion of CLEO's ongoing clinical trials in the U.S. and Australia, which will enable CLEO to submit its 510(k) application to the FDA.

Negotiations with key FDA-approved CMOs are in their final stages, with the ultimate decision to be based upon manufacturing capability, regulatory compliance and ability to scale to production to meet demand upon product launch.

Commenting on the milestone achievement, CLEO's Chief Executive Officer, Dr Richard Allman, said:

"The commencement of technology transfer marks a pivotal milestone in CLEO's strategic pathway toward commercialisation. During this phase, we refine and scale our assay technology, to ensure the Company is well positioned to progress its Ovarian Cancer test from prototype production to a commercially available, FDA-compliant diagnostic kit.

More broadly, this step is also integral to our strategy of delivering a highly accurate, accessible cancer diagnostic solution that addresses a critical and global unmet need in population screening for Ovarian Cancer detection."

-ENDS-

This ASX announcement was authorised for release by the Board of Cleo Diagnostics Limited.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0600
office@cleodx.com

Dayna Louca
Head of Corporate Development
+61 409 581 972
dayna.louca@cleodx.com

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

About Cleo Diagnostics Ltd ASX:COV

CLEO is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, CLEO has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. CLEO is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

